I always assume that an inventive drug Co put together from perhaps buying the majority interest in the patents of a promising drug platform ( from a university or other drug Co.) is only focused on financing and managing the drug trials, and will usually outsource the difficult phase of the manufacturing process. But you of course know the whole routine. Am I wrong in thinking Sloan Kettering can act like a usual drug manufacturing entity?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.